SCHEMBL514093

SCHEMBL514093

CCCC#CCCCCCCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.56
HMGCR P04035 3/20 0.56
RECQL P46063 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
TSHR P16473 1/20 0.50
THRB P10828 1/20 0.50
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
ALDH1A1 P00352 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
ALOX12 P18054 1/20 0.46
BLM P54132 1/20 0.46
KMT2A Q03164 1/20 0.46
MCL1 Q07820 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
RAB9A P51151 1/20 0.43
EPHX2 P34913 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9015878 1.00 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9836895 1.00 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9015933 1.00 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9015828 1.00 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9015881 1.00 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9015929 1.00 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9943966 1.00 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9015897 1.00 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL512606 1.00 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL512382 1.00 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS FLAGSHIP LABS 114, INC. (US) 2026-05-14 US claimed
EP-4687854-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY Flagship Labs 114, Inc. (US) 2026-02-11 EP claimed
WO-2024211865-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY OMEGA THERAPEUTICS, INC. (US) 2024-10-10 WO claimed
WO-2024073678-A2 PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE OMEGA THERAPEUTICS, INC. (US) 2024-04-04 WO claimed
WO-2023225621-A2 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS OMEGA THERAPEUTICS, INC. (US) 2023-11-23 WO claimed
EP-3642211-B1 ALDIMINOSILANES SIKA TECH AG (CH) 2023-04-05 EP claimed
EP-3642252-B1 LATENT CURING AGENT AND CURABLE POLYURETHANE COMPOSITION SIKA TECH AG (CH) 2021-12-08 EP claimed
EP-2181763-B1 Catalyst and process for alkoxylation SHELL INT RESEARCH (NL) 2012-06-20 EP claimed
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS FLAGSHIP LABS 114, INC. (US) 2026-05-14 US disclosed
US-12620622-B2 Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same DAIKIN INDUSTRIES, LTD. (JP) 2026-05-05 US disclosed
EP-4687854-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY Flagship Labs 114, Inc. (US) 2026-02-11 EP disclosed
US-20250260063-A1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY DAIKIN INDUSTRIES, LTD. (JP) 2025-08-14 US disclosed
EP-3780232-B1 ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE DAIKIN IND LTD (JP) 2025-07-30 EP disclosed
US-20250233206-A1 NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2025-07-17 US disclosed
CN-1216857-C Aniline-derived ligands for thyroid receptor BRISTOL MYERS SQUIBB CO (US) 2005-08-31 CN disclosed
CN-1441785-A Tetrahydroixoquinoline analogs useful as growth hormone secretagogues BRISTOL MYERS SQUIBB CO (US) 2003-09-10 CN disclosed
CN-1436192-A HMG-CoA reductase inhibitors and method BRISTOL MYERS SQUIBB CO (US) 2003-08-13 CN disclosed
CN-1436174-A HMG-CoA reductase inhibitors and their use as medicaments for treatment of cholesterol related diseases BRISTOL MYERS SQUIBB CO (US) 2003-08-13 CN disclosed
CN-1418185-A Aniline-derived thyroid receptor ligands BRISTOL MYERS SQUIBB CO (US) 2003-05-14 CN disclosed
EP-0748823-A1 Catalyst composition and process for the production of olefinic polymers NIPPON OIL CO. LTD. (JP) 1996-12-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS NSUN3, NSUN2, LDLR PTPN7 2194/4885HMGCR 460/4885RECQL 976/4885
US-12620622-B2 Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same ASH2L, OLA1, ODC1 PTPN7 2759/4885HMGCR 3484/4885RECQL 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.